このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Revvity 過去の業績

過去基準チェック /26

Revvityは、平均年間27.9%の収益成長を遂げていますが、 Life Sciences業界の収益は、年間成長しています。収益は、平均年間19.7% 7.3%収益成長率で成長しています。 Revvityの自己資本利益率は4.4%であり、純利益率は11.7%です。

主要情報

27.9%

収益成長率

26.0%

EPS成長率

Life Sciences 業界の成長	12.9%
収益成長率	7.3%
株主資本利益率	4.4%
ネット・マージン	11.7%
次回の業績アップデート	01 Aug 2023

Recent updates

収支内訳

Revvity の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

BMV:RVTY * 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
02 Apr 23	3,024	353	942	216
01 Jan 23	3,312	513	965	216
02 Oct 22	3,302	606	940	206
03 Jul 22	3,452	644	927	202
03 Apr 22	3,483	694	885	195
02 Jan 22	3,828	889	869	199
03 Oct 21	4,155	1,086	893	197
04 Jul 21	4,257	1,155	893	197
04 Apr 21	4,438	1,074	961	217
03 Jan 21	2,663	631	729	146
04 Oct 20	3,234	412	887	196
05 Jul 20	2,977	294	866	191
05 Apr 20	2,887	226	845	190
29 Dec 19	2,884	228	833	189
29 Sep 19	2,835	235	806	194
30 Jun 19	2,802	251	794	197
31 Mar 19	2,783	247	790	196
30 Dec 18	2,778	237	809	194
30 Sep 18	2,663	128	761	180
01 Jul 18	2,543	149	719	166
01 Apr 18	2,387	147	667	152
31 Dec 17	2,257	157	615	139
01 Oct 17	2,182	258	587	135
02 Jul 17	2,142	215	580	129
02 Apr 17	2,132	210	584	128
01 Jan 17	2,116	216	585	124
02 Oct 16	1,999	198	574	108
03 Jul 16	2,048	199	583	110
03 Apr 16	2,076	190	583	110
03 Jan 16	2,105	189	586	113
04 Oct 15	2,263	176	661	127
28 Jun 15	2,241	164	657	126
29 Mar 15	2,234	167	656	124
28 Dec 14	2,070	130	648	108
28 Sep 14	2,221	203	576	123
29 Jun 14	2,201	201	577	124
30 Mar 14	2,185	176	579	128
29 Dec 13	2,158	174	581	132
29 Sep 13	2,139	85	622	133
30 Jun 13	2,126	73	627	134
31 Mar 13	2,107	79	628	134
30 Dec 12	2,105	71	628	132
30 Sep 12	2,082	1	668	131

質の高い収益: RVTY *は高品質の収益を持っています。

利益率の向上: RVTY *の現在の純利益率 (11.7%)は、昨年(20%)よりも低くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: RVTY *の収益は過去 5 年間で年間27.9%増加しました。

成長の加速: RVTY *は過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: RVTY *は過去 1 年間で収益成長率がマイナス ( -49.2% ) となったため、 Life Sciences業界平均 ( -1.7% ) と比較することが困難です。

株主資本利益率

高いROE: RVTY *の自己資本利益率 ( 4.4% ) は低いとみなされます。

Revvity 過去の業績

過去 基準チェック /26

主要情報

最近の業績更新

Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Revvity, Inc. to Report Q4, 2023 Results on Feb 01, 2024

Revvity, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Revvity, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Full year 2022 earnings released: EPS: US$4.13 (vs US$8.12 in FY 2021)

PerkinElmer, Inc. to Report Q4, 2022 Results on Feb 14, 2023

Recent updates

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Revvity, Inc. Declares Quarterly Dividend, Payable on August 9, 2024

Revvity Unveils A New Era of Automated Tuberculosis Testing

Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication

Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research

Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions

Revvity Showcases Cutting-Edge Solutions at SLAS2024

Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024

Revvity, Inc., Annual General Meeting, Apr 23, 2024

Revvity, Inc. Announces Board Elections, Effective February 1, 2024

Revvity, Inc. to Report Q4, 2023 Results on Feb 01, 2024

Revvity, Inc. Provides Revenue Guidance for the Fourth Quarter 2023

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

Revvity Board Declares Quarterly Dividend, Payable on February 9, 2024

Revvity, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

Revvity, Inc. Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

Revvity Declares Quarterly Dividend, Payable on November 10, 2023

Revvity, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research

Revvity, Inc. Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development

Revvity, Inc. (NYSE:PKI) announces an Equity Buyback for $600 million worth of its shares.

Upcoming dividend of US$0.07 per share at 0.2% yield

Insufficient new directors

Insufficient new directors

PerkinElmer, Inc. Provides Earnings Guidance for the Full Year of 2023

Full year 2022 earnings released: EPS: US$4.13 (vs US$8.12 in FY 2021)

PerkinElmer, Inc. Declares Regular Quarterly Dividend, Payable on May 12, 2023

Upcoming dividend of US$0.07 per share

PerkinElmer, Inc. to Report Q4, 2022 Results on Feb 14, 2023

Third quarter 2022 earnings released: EPS: US$0.55 (vs US$0.94 in 3Q 2021)

PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns

Third quarter 2022 earnings released: EPS: US$0.55 (vs US$1.12 in 3Q 2021)

PerkinElmer, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

PerkinElmer, Inc. Declares a Regular Quarterly Dividend, Payable on February 10, 2023

PerkinElmer, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Upcoming dividend of US$0.07 per share

PerkinElmer, Inc. Unveils Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing

Perkinelmer’S Oxford Immunotec Receives U.S. Fda Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection

PerkinElmer, Inc. Announces Appointment of Maxwell Krakowiak as Senior Vice President, Effective September 6, 2022

Second quarter 2022 earnings released: EPS: US$1.42 (vs US$2.20 in 2Q 2021)

New Mountain Capital, L.L.C. entered into a definitive agreement with the intention to acquire Applied, Food and Enterprise Services businesses of PerkinElmer, Inc. (NYSE:PKI) for $2.5 billion.

PerkinElmer, Inc. Elects Michelle McMurry-Heath to its Board of Directors

PerkinElmer, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Upcoming dividend of US$0.07 per share

PerkinElmer, Inc.(NYSE:PKI) dropped from Russell 1000 Value-Defensive Index

Perkinelmer Introduces Next Generation, Automated Gas Chromatography Platform

PerkinElmer Expands Food Safety Testing Portfolio with AOAC Certified Microbial Count Plates

PerkinElmer, Inc. Launches BioQule NGS System to Automate Library Preparation

First quarter 2022 earnings released: EPS: US$1.40 (vs US$3.39 in 1Q 2021)

PerkinElmer, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2022

Upcoming dividend of US$0.07 per share

PerkinElmer, Inc. to Report Q1, 2022 Results on May 03, 2022

PerkinElmer, Inc. Expands in Vivo Instruments Portfolio with Hands-Free, High-throughput Vega® Widefield Preclinical Ultrasound Imaging System

PerkinElmer, Inc. Introduces First Ready-To-Use HTRF and AlphaLISA Assay Kits for CHO HCP Impurities Detection and Quantification

Perkinelmer, Inc. Launches ChemDraw V21 Software, Empowering Researchers to Rapidly Create Chemically Intelligent Microsoft Powerpoint Reports

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

PerkinElmer, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2022

PerkinElmer, Inc. Declares Quarterly Dividend, Payable on May 13, 2022

PerkinElmer, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2021

PerkinElmer India Welcomes Everest Instruments as its Primary, In-Country Channel Partner for Milk and Dairy Testing Solutions

PerkinElmer Launches NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 to Strengthen SARS-CoV-2 Surveillance

PerkinElmer, Inc. Launches Cloud Based Solution to Enable Remote Lab Management

Third quarter 2021 earnings released: EPS US$1.11 (vs US$1.58 in 3Q 2020)

過去基準チェック /26